Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ImmunityBio (IBRX) Asset Writedowns and Impairment: 2014-2023

Historic Asset Writedowns and Impairment for ImmunityBio (IBRX) over the last 5 years, with Dec 2023 value amounting to $886,000.

  • ImmunityBio's Asset Writedowns and Impairment rose 35.89% to $886,000 in Q4 2023 from the same period last year, while for Dec 2023 it was $12.2 million, marking a year-over-year increase of 1.34%. This contributed to the annual value of $886,000 for FY2023, which is 33.53% down from last year.
  • As of FY2023, ImmunityBio's Asset Writedowns and Impairment stood at $886,000, which was down 33.53% from $1.3 million recorded in FY2022.
  • ImmunityBio's 5-year Asset Writedowns and Impairment high stood at $10.7 million for FY2020, and its period low was $886,000 during FY2023.
  • Over the past 2 years, ImmunityBio's median Asset Writedowns and Impairment value was $1.1 million (recorded in 2022), while the average stood at $1.1 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first soared by 571.69% in 2020, then crashed by 33.53% in 2023.
  • Over the past 4 years, ImmunityBio's Asset Writedowns and Impairment (Yearly) stood at $1.6 million in 2019, then skyrocketed by 571.69% to $10.7 million in 2020, then reached $1.3 million in 2022, then plummeted by 33.53% to $886,000 in 2023.